News

– Preclinical research to focus on sleep, inflammation and efficacy of the NTS compound NTS-104 in TBI –

NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company developing a portfolio of disease-modifying therapeutic candidates to treat the devastating effects of acquired brain injury, today announced that it has awarded a grant to Jonathan Lifshitz, PhD, professor at the University of Arizona College of Medicine – Phoenix who leads the Neurotrauma & Social Impact research team, to conduct preclinical research on its novel neuroprotective compound NTS-104 in mild traumatic brain injury (mTBI), with a focus on addressing clinically-relevant outcome measures such as anxiety, depression, cognitive dysfunction, and sleep-wake disturbances.

– Landmark study in mild TBI (mTBI), supported in part by a grant from NeuroTrauma Sciences, helps define CT (computed tomography) scan features associated with adverse outcomes after mTBI   –

A head computed tomography (CT) with positive results for acute intracranial hemorrhage is the gold-standard diagnostic biomarker for acute traumatic brain injury (TBI).  In moderate to severe TBI, some CT features have been shown to be associated with certain outcomes.  In mild TBI, distribution and co-occurrence of pathological CT features and their prognostic importance are not well understood.

In a first-of-its-kind study, TRACK-TBI investigators, under the direction of Geoffrey T. Manley, MD, PhD, Department of Neurological Surgery, University of California, San Francisco, and with external validation from CENTER-TBI, under the direction of Andrew I.R. Maas, MD, PhD and Geoffrey T. Manley, MD, PhD, identified pathological CT features associated with adverse outcomes after mTBI and concluded that pathological features on head computed tomography carried different implications for mild traumatic brain injury prognosis to one year…